Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer may possibly lessen doravirine plasma concentrations and/or effects. Opportunity for loss of virologic reaction and possible resistance to doravirine.
pentobarbital will minimize the extent or influence of conivaptan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lessen the extent or impact of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital will lower the extent or outcome of bosentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
pentobarbital will reduce the level or effect of copyright topical by impacting hepatic enzyme CYP2B6 metabolism. Minimal/Importance Unidentified.
pentobarbital will lessen the level or effect of triamcinolone acetonide injectable suspension by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
fentanyl transdermal and pentobarbital equally raise sedation. Stay clear of or Use Alternate Drug. Restrict use to people for whom substitute remedy choices are inadequate
Contraindicated read more (1)pentobarbital will decrease the extent or impact of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the extent or result of docetaxel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unfamiliar.
pentobarbital will lower the extent or effect of dexamethasone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will reduce the extent or influence of duvelisib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Coadministration with a strong CYP3A inducer decreases duvelisib area under the curve (AUC), which can decrease duvelisib efficacy.
pentobarbital will decrease the level or result of buprenorphine, prolonged-acting injection by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. People who transfer to buprenorphine lengthy-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers needs to be monitored to make certain buprenorphine plasma concentrations are satisfactory.
pentobarbital will lower the level or result of dienogest/estradiol valerate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Women shouldn't select estradiol valerate/dienogest as their contraceptive whilst making use of strong CYP3A4 inducers as a result of potential lower in contraceptive efficacy.
pentobarbital will minimize the extent or influence of isavuconazonium sulfate by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.